大行評級|花旗:下調國藥控股目標價至26港元 下調2024至26年每股盈測
花旗發表報吿指,國藥控股在上半年業績電話會議中,管理層指出7月份營收開始復甦,並錄得按年增長,預期復甦勢頭將於下半年持續,下半年毛利率料較上半年有所改善。上半年公司財務費用比率下降11個基點至0.36%。管理層預期,在低利率環境下,下半年財務費用率將會降低。該行降國藥2024至2026年各年每股盈測分別12%、12%及12%,以反映最新收入增長放緩及利潤率趨勢,對國藥目標價由30港元降至26港元,評級“買入”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.